Morbid Rates After Spiriva Chronic Obstructive Pulmonary Disease (COPD) Protocol Change

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

3015000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-04-01

Study Completion Date

2021-07-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study evaluates hospitalizations and mortality in patients with Chronic Obstructive Pulmonary Disease (COPD) before and after the implantation of a new COPD treatment plan (replacement of tiotropium soft mist inhaler for glycopyrronium dry powder inhaler) by the Health State Secretariat of Federal District in Brazil.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study on Whether Patients Prefer the Spiriva® Respimat® or the Spiriva® Handihaler® for Treating Their Chronic Obstructive Pulmonary Disease (COPD)

NCT03964207

Pulmonary Disease, Chronic Obstructive

COMPLETED PHASE4

Effectiveness and Handling of Spiolto® Respimat ® in COPD Patients - Italy

NCT03003494

Pulmonary Disease, Chronic Obstructive

COMPLETED

Assessment of Health-related Quality of Life After Switching COPD Patients From a Dry Powder Inhaler to a Soft Mist Inhaler Remaining on the Same Inhalative Drug

NCT05362487

Pulmonary Disease, Chronic Obstructive

TERMINATED

Survival Of Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT00268216

Pulmonary Disease, Chronic Obstructive

COMPLETED PHASE3

Efficacy and Safety Comparison of Tiotropium Daily + Salmeterol Daily or Twice Daily Versus Tiotropium Daily in Patients With COPD

NCT00662792

Pulmonary Disease, Chronic Obstructive

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pulmonary Disease, Chronic Obstructive

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients diagnosed with COPD, admitted to the hospital with acute exacerbations

Patients over 40 years of age, diagnosed with Chronic Obstructive Pulmonary Disease (COPD), admitted to the hospital with acute exacerbations as recorded in the DATASUS (Unified Health Brazilian System Informatics Department (in Portuguese) between August 2017 and July 2019. Patients were treated with either Tiotropium bromide in soft mist inhaler (SPIRIVA® RESPIMAT®) or with Glycopyrronium bromide in dry powder inhaler (Seebri® Breezhaler®) as part of the treatment plan for Chronic Obstructive Pulmonary Disease (COPD) defined by the Health State Secretariat of Distrito Federal (DF) in Brazil.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients older than 40 years of age at the time of hospital admission
* Diagnosis of Chronic Obstructive Pulmonary Disease (COPD) according to the International Statistical Classification of Diseases and Related Health Problems Version 10 (ICD-10) established by the Health Care Protocol of the Health Secretariat of Federal District (SES/DF), with the following codes:

* J41.0 - Simple chronic bronchitis
* J41.1 - Mucopurulent chronic bronchitis
* J41.8 - Mixed simple and mucopurulent chronic bronchitis
* J42 - Unspecified chronic bronchitis
* J43.1 - Panlobular emphysema
* J43.2 - Centrilobular emphysema
* J43.8 - Other emphysema
* J43.9 - Emphysema, unspecified
* J44.0 - Chronic obstructive pulmonary disease with acute lower respiratory infection
* J44.1 - Chronic obstructive pulmonary disease with acute exacerbation, unspecified
* J44.8 - Other specified chronic obstructive pulmonary disease
* J44.9 - Chronic obstructive pulmonary disease, unspecified